Albuterol Plus Budesonide Reduces Exacerbations in Asthma
As-needed use of a fixed combination of albuterol and budesonide is associated with a lower risk for severe asthma exacerbations.
Treatments
Recent Cancer Treatment Linked to Worse COVID-19 Outcomes
Patients diagnosed with cancer more than one year ago and those not receiving active treatment are not at heightened risk for worse COVID-19.
Rare Cases of COVID-19 Relapse Seen With Pfizer Pill
Rare cases of COVID-19 patients relapsing after taking the antiviral pill Paxlovid are raising questions among some experts.
Patient-Dependent Factors and Decreased PA Pressure Monitoring During the COVID-19 Pandemic
A study examining hemodynamically guided management of patients with chronic HF found significant changes in clinical outcomes during the COVID-19 pandemic.
Efficacy of Monoclonal Antibodies for COVID-19 Not Associated With Early vs Late Administration
In this retrospective cohort study, researchers assessed the rate of treatment failure among patients with COVID-19 infection who received bamlanivimab vs those who received casirivimab/imdevimab.
First Generic of Symbicort Receives FDA Approval
The U.S. FDA approved the first generic of Symbicort Inhalation Aerosol to treat asthma in patients 6 years and older and for maintenance treatment in patients with COPD.
Early Use of COVID-19 Convalescent Plasma Reduces Hospitalization Risk
COVID-19 convalescent plasma administered to mostly unvaccinated outpatients within nine days after symptom onset reduced the risk of progression of COVID-19 leading to hospitalization.
Outcomes of Concomitant Bedaquiline and Delamanid in Patients With Multidrug-Resistant Tuberculosis
Researchers evaluated the safety, effectiveness, and cardiotoxity risk associated with concomitant treatment with bedaquiline and delamanid in patients with multidrug-resistant tuberculosis infection.
ACP Releases Final Update on the Effect of Remdesivir in Adults With COVID-19
The American College of Physicians provides an overview of the final update to the rapid, living practice points on the use of remdesivir for the treatment of COVID-19 infection.
CDC Releases Interim Guidance on a Novel Treatment Regimen for Drug-Susceptible Tuberculosis
Investigators at the Centers for Disease Control and Prevention evaluated the effect of a novel 4-month regimen for the treatment of drug-susceptible tuberculosis infection.
- Loading...
Loading...
Next post in Tuberculosis
Loading... 
Loading...